Q3 EPS Forecast for TransMedics Group Increased by Analyst

TransMedics Group, Inc. (NASDAQ:TMDX) – Equities researchers at William Blair boosted their Q3 2026 EPS estimates for shares of TransMedics Group in a research report issued to clients and investors on Thursday, October 23rd. William Blair analyst R. Daniels now anticipates that the company will earn $0.65 per share for the quarter, up from their prior estimate of $0.64. The consensus estimate for TransMedics Group’s current full-year earnings is $1.00 per share.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to the consensus estimate of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS.

A number of other equities analysts also recently issued reports on TMDX. Wall Street Zen raised TransMedics Group from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of TransMedics Group in a report on Friday. Morgan Stanley raised their target price on TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Zacks Research lowered shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Jefferies Financial Group began coverage on shares of TransMedics Group in a report on Monday, October 13th. They issued a “buy” rating and a $145.00 price target for the company. Eight analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus price target of $130.73.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $130.52 on Monday. TransMedics Group has a 52 week low of $55.00 and a 52 week high of $145.50. The company has a 50-day moving average price of $115.94 and a 200 day moving average price of $115.84. The company has a market cap of $4.45 billion, a P/E ratio of 67.63 and a beta of 2.08. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently made changes to their positions in the business. Opal Wealth Advisors LLC purchased a new position in TransMedics Group during the 2nd quarter valued at about $26,000. Salomon & Ludwin LLC acquired a new stake in shares of TransMedics Group in the third quarter valued at approximately $28,000. Smartleaf Asset Management LLC increased its stake in shares of TransMedics Group by 44.3% during the 1st quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after purchasing an additional 135 shares in the last quarter. Quarry LP raised its position in shares of TransMedics Group by 88.5% during the 1st quarter. Quarry LP now owns 592 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the last quarter. Finally, Sound Income Strategies LLC purchased a new stake in TransMedics Group in the 2nd quarter valued at approximately $48,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.